Opportunity
Healthcare-associated infections remain a significant clinical and economic burden, particularly among vulnerable patients exposed to broad-spectrum antibiotics.
Antibiotic treatment can disrupt the gut microbiome, reducing its natural protective functions and creating an environment where potentially pathogenic organisms can proliferate.
KeepBio is developing a microbiome-based approach designed to help rebuild a healthy gut microbiome and support its natural protective functions.
10M Patients exposed to broad-spectrum antibiotics annually
$45B Annual economic burden associated with HAIs
$3B Estimated ICU opportunity
$600M Estimated Leukemia opportunity
Focused entry. Broader platform potential.
Our initial development programs focused on patient populations where antibiotic exposure, microbiome disruption, and infection risk converge;
ICU/Critical Care Leukemia Recurrent UTIs HCT/Transplants Other High-Risk